Propuesta para manejar el flujo de efectivo en la Radiodifusora XHTNO-FM TULANCINGO

Ranbaxy Community Health Care Society

Ranbaxy has a strong element of Corporate Social Responsibility inscribed in its values and its concern for the society extends well beyond its business motives.

The company does not view success and achievements in terms of commercial gains only but firmly believes that corporate social responsibility is the key for providing a deep symbiotic relationship that exists between the company and the environment it functions. Over two decades ago, in 1979, in the wake of grim health scenario of India, Ranbaxy realized the urgency to reach out to those who had little or no access even to basic health care and instituted ‘Ranbaxy Rural Development Trust’.

The main objective of the programme was to deliver primary health care to the underserved and underprivileged section of the society to achieve positive health for them and thus to contribute to the national objective ‘Health For All’. As the scope of the programme and company’s commitment grew, in 1994, a professionally managed, nonprofit, independent body ‘Ranbaxy Community Health Care Society’ (RCHS) was established against the backdrop of full moral and financial support of the company.

Community participation

It was recognized that over 70 percent of the deliveries in RCHS service areas were conducted at home by either untrained or improperly trained ‘dais'. Thus, as a strategy, two-phase

intervention was planned where the RCHS Medical officers were trained to train the ‘dais' in the first phase and training of ‘dais' from the community was done in the second phase.

RCHS has established community based local groups like health committees, women groups and other interactive groups like “dais”, “anganwari” workers, volunteers, adolescents and breast-feeding support groups to promote community involvement and self-sustainability.

Scientific approach

With a view to plan future strategies for need based interventions, RCHS regularly monitors and records all vital events such as live births, infant deaths, maternal deaths and abortions etc.

Special attention is given to promote ORS in Diarrhea and early diagnosis and appropriate treatment of Pneumonia. Focused work with precise risk groups like pregnant women, lactating mothers, newly married eligible couples and adolescent girls to prevent low birth weight and anemia in pregnancy, including referral services for dealing with obstetrical emergencies are some of the steps taken in order to bring down the infant and maternal mortality rates in RCHS

areas.

Ranbaxy Science Foundation

Ranbaxy Laboratories Limited incorporated Ranbaxy Research Foundation in 1985 and was later reconstituted as a separate society as Ranbaxy Science Foundation and registered under the Societies Act in May 1994. with an implicit mission of giving impetus to research activity and help in reviving India’s great scientific tradition. The Foundation instituted Ranbaxy Research Awards to recognize original outstanding contributions in the fields of Medical and Pharmaceutical Sciences. Every year the Foundation invites nominations for 4 awards – 3 Awards for Rs. 1,00,000/- each in the fields of Medical Sciences in Basic. Applied and Clinical and 1 Awards of Rs. 1,00,000/- in the field of Pharmaceutical Sciences. So far 104 scientists have been honored by the Foundation.

Ranbaxy Science foundation (RSF) is a non profit organization dedicated to promote scientific endeavors in the country by encouraging and rewarding and channeling national and international knowledge and expertise on subjects connected with treatment of diseases afflicting mankind. To achieve these objectives, the Foundation conducts Round Table Conferences on topics concerning public health and symposia on topics at the cutting edge of research in medical sciences to explore the latest in the selected area of specialty and its potential application for the benefit of mankind.

Being committed to recognizing and furthering excellence, the Foundation has also initiated “Research Scholarship Awards for the Young Scientists” with an aim to stimulate their interest in research.

Ranbaxy's Anti-Malaria collaborative research program

Ranbaxy has been working on the anti-malaria collaborative research project since May 2003.

Although ant malarial drugs have a large market, it is a market with very limited resources.

Together with the challenges of drug resistance, poor health systems, lack of affordable, safe and convenient treatment options, malaria treatment represents one of the largest unmet medical needs. Ranbaxy is developing a synthetic peroxide ant malarial drug in order to address this unmet need. The Company has obtained approval from the Drug Controller General of India to initiate Phase III human clinical trials for this drug in India. Ranbaxy plans to seek regulatory approval in other countries outside India to the Phase-III clinical trials.

The production of RBx 11160 (Arterolane) is not dependent on the availability of agricultural resources (from which the current Artemisinin drugs are derived), giving it a clear advantage in product scale-up and cost.

Ranbaxy is committed to developing a drug that is not only safe and effective, but also affordable to people in India, Africa and other disease endemic countries.

Ranbaxy comprehensive anti-HIV portfolio comprises Bio-Equivalent Anti-Retrovirals (ARVs) and Anti-Infectives for Opportunistic infections

Ranbaxy, in its endeavor to make ARVs accessible to patients around the world, is leveraging its global network of offices, affiliates, joint ventures and alliances. With Ranbaxy products being marketed in over 125 countries and ground operations in 49 countries, Ranbaxy provides pre &

post sales support to institutions, NGOs, and Ministries of Health, making Ranbaxy ARVs available in their respective treatment programs

Encouraged by the positive response to its efforts to make quality anti-HIV generics, Ranbaxy is committed to working on all possible fronts and seeking partnerships to improve access to these medicines.

Ranbaxy offers a complete basket of pharmaceuticals for several first line HAART regimens.

The current portfolio is the largest range of bio-equivalent generic ARVs available from a single company. These products are manufactured at Ranbaxy's WHO prequalified and USFDA approved facilities.

• Several Ranbaxy ARVs approved by USFDA and WHO

• First Asian pharmaceutical company to get approval for a generic ARV from USFDA

• Over 250 approvals of ARVs across 40 countries, with 130 more in pipeline

• Only company using both WHO & USFDA approved API supplier

• Bioequivalence studies conducted at leading CROs in North America

• All ARVs comply with Zone IV and Zone II stability requirements

• Leading supplier of ARVs to global NGOs, Institutions & Government programs

• Ranbaxy's ARVs have catered to treatment programs in over 50 countries globally

• Ranbaxy's quality FDCs reduce pill burden and improve patient compliance

Financial analysis refers to an assessment of the viability, stability and profitability of a business, sub-business or project. Strengths and weaknesses of the firm by properly establishing relationship between the items of the balance sheet and the profit and loss account.

Financial statements are prepared to meet external reporting obligations and also for decision making purposes. They play a dominant role in setting the framework of managerial decisions.

But the information provided in the financial statements is not an end in itself as no meaningful conclusions can be drawn from these statements alone. However, the information provided in the financial statements is of immense use in making decisions through analysis and interpretation of financial statements. The financial statements are of much interest to a number of groups of persons. Apart from management there are other interested parties like shareholders, debenture holders, potential investors – large and small, bankers, trade creditors, journalists, legislators and politicians who are increasingly getting interested in the analysis and interpretation of financial statements. “To interpret, means to put the meaning of a statement into simple terms for the benefit of a person.” This is essentially done through the tools of analysis such as comparative statements, common size statements and ratio analysis. These tools may be compared with the laboratory tests, which aid a physician in the diagnosis of a malady. Just as laboratory test are

similarly the tools of analysis only help in establishing relationship between one accounting figure and another in the financial statements and go no far. It is the expert who has to grasp the significance of related figures and form an opinion as to whether the ratio calculated indicates a favorable or adverse state of affairs. Therefore while analysis comprises resolving the statements by breaking them into simpler statements by a process or rearranging, regrouping and the calculation of ratios, interpretation is the mental process of understanding the terms of such statements and forming opinions of inferences about the financial health, profitability, efficiency and such other aspects of the undertaking.

There are various methods or techniques that are used in analyzing financial statements, such as comparative statements, schedule of changes in working capital, common size percentages, funds analysis, trend analysis, and ratios analysis.

Goals

Financial analysts often assess the firm's:

1. Profitability - its ability to earn income and sustain growth in both short-term and long-term.

A company's degree of profitability is usually based on the income statement, which reports on the company's results of operations;

2. Solvency - its ability to pay its obligation to creditors and other third parties in the long-term;

3. Liquidity - its ability to maintain positive cash flow, while satisfying immediate obligations;

Both 2 and 3 are based on the company's balance sheet, which indicates the financial condition of a business as of a given point in time.

4. Stability- the firm's ability to remain in business in the long run, without having to sustain significant losses in the conduct of its business. Assessing a company's stability requires the use of the income statement and the balance sheet, as well as other financial and non-financial indicators

Methods

Financial analysts often compare financial ratios (of solvency, profitability, growth, etc.):

• Past Performance - Across historical time periods for the same firm (the last 5 years for example),

• Future Performance - Using historical figures and certain mathematical and statistical techniques, including present and future values, This extrapolation method is the main source of errors in financial analysis as past statistics can be poor predictors of future

• Comparative Performance - Comparison between similar firms.